Month: December 2018

24
Dec 2018

Bionest

New Approaches to an Earlier Alzheimer’s Disease Diagnosis

We have written previously about the need for earlier diagnosis for Alzheimer’s disease (AD) and other dementias, a capability that could both aid in the discovery and the development of new therapies, and increase the chances for better patient outcomes in slowing or preventing cognitive decline. Recently, researchers have presented data on several new non-invasive...
18
Dec 2018

Bionest

Neuromuscular Drug Development Summit

At the end of October, we attended the inaugural Neuromuscular Drug Development Summit. This new meeting brought together thought leaders from industry, academia, and the patient advocacy community to discuss scientific progress and issues affecting companies developing drugs for these mostly rare diseases.   Neuromuscular diseases — such as muscular dystrophies, motor neuron diseases, mitochondrial...
10
Dec 2018

Bionest

No Signs of Slowdown in NGS Sequencing Market

A couple of recent announcements in the next-generation sequencing (NGS) market got our attention as strong signs that both technology and applications are rapidly diversifying within that arena. It’s continued evidence that the NGS market is not only expanding rapidly, but also that there are no limits in sight to the demand for genomic information....
6
Dec 2018

Bionest

Report on ESMO 2018 – Part Two

We recently returned from the European Society for Medical Oncology (ESMO) meeting where conference news highlighted the increased movement of targeted therapies and immunotherapies into adjuvant and early-stage cancer settings. Read our earlier report on combination therapy trials in melanoma, colon cancer and breast cancer, including triple-negative breast cancer. Here, we cover other targeted therapies....
3
Dec 2018

Bionest

Report on ESMO 2018 – Part One

We recently returned from the European Society for Medical Oncology (ESMO) meeting where conference news highlighted the increased movement of targeted therapies and immunotherapies into adjuvant and early-stage cancer settings, plus plenty of positive data from a variety of combination therapy trials in breast cancer, including triple-negative breast cancer.   (Neo)Adjuvant Treatment Gets a Boost  ...